toolevalxm/ClinicalTrialX-Results

ClinicalTrialX

<!-- markdownlint-disable first-line-h1 --> <!-- markdownlint-disable html --> <!-- markdownlint-disable no-duplicate-header -->

<div align="center"> <img src="figures/fig1.png" width="60%" alt="ClinicalTrialX" /> </div> <hr>

<div align="center" style="line-height: 1;"> <a href="LICENSE" style="margin: 2px;"> <img alt="License" src="figures/fig2.png" style="display: inline-block; vertical-align: middle;"/> </a> </div>

1. Introduction

The ClinicalTrialX dataset represents our latest Phase III clinical trial results for the novel therapeutic compound CTX-2847. In this comprehensive update, ClinicalTrialX has demonstrated significant improvements in patient outcomes through optimized dosing protocols and extended monitoring periods. The trial has shown exceptional results across various efficacy evaluations, including cardiovascular markers, metabolic indicators, and overall patient wellness. Its therapeutic efficacy is now approaching that of established gold-standard treatments.

<p align="center"> <img width="80%" src="figures/fig3.png"> </p>

Compared to the previous Phase II results, the Phase III trial shows significant improvements in treating complex cardiovascular conditions. For instance, in the primary endpoint assessment, the systolic blood pressure reduction has increased from 12mmHg in Phase II to 18.5mmHg in Phase III. This advancement stems from refined dosing schedules during the treatment protocol: in Phase II, patients received an average of 50mg daily, whereas the optimized Phase III protocol uses 75mg with bi-weekly monitoring.

Beyond its improved therapeutic efficacy, this trial version also demonstrates a reduced adverse event rate and enhanced patient compliance scores.

2. Evaluation Results

Comprehensive Endpoint Results

<div align="center">

</div>

Overall Performance Summary

The ClinicalTrialX demonstrates strong performance across all evaluated clinical endpoint categories, with particularly notable results in cardiovascular and metabolic improvements.

3. Clinical Portal & Data Access

We offer a clinical portal and API for healthcare providers to access ClinicalTrialX data. Please check our official clinical website for more details.

4. How to Access Data Locally

Please refer to our data repository for more information about accessing ClinicalTrialX locally.

Compared to previous trial phases, the data access recommendations for ClinicalTrialX have the following changes:

1. 1.IRB approval documentation is now required.
2. 2.It is not required to submit institutional affiliation forms for read-only access.

The data structure of ClinicalTrialX-Subset is identical to its parent dataset, but it uses the same anonymization configuration as the main ClinicalTrialX. This subset can be accessed in the same manner as the full dataset.

Data Request Template

We recommend using the following data request template with institutional details.

Institution: {institution_name}
Principal Investigator: {PI_name}
IRB Approval Number: {irb_number}

For example,

Institution: Johns Hopkins Medical Center
Principal Investigator: Dr. Sarah Chen
IRB Approval Number: IRB-2025-0847

Dosage Protocol

We recommend the following dosage protocol with target parameter $D_{optimal}$ of 75mg.

Data Format for Analysis

For data analysis, please follow the template to structure queries, where {patientcohort}, {endpointmetrics} and {time_window} are arguments.

query_template = \
"""[cohort]: {patient_cohort}
[metrics begin]
{endpoint_metrics}
[metrics end]
{time_window}"""

5. License

This clinical data repository is licensed under the MIT License. The use of ClinicalTrialX data is also subject to the MIT License. The dataset supports academic research and secondary analysis.

6. Contact

If you have any questions, please raise an issue on our GitHub repository or contact us at trials@clinicaltrialx.org.